clinical trials semaglutide Improves Weight Loss in Type 1 Diabetes Patients Enrollment Excellence in Phase-3 Semaglutide

Obesity 31 , 537544 (2023)

Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 20122023: A US Cohort Study

[1] [2] These mechanisms typically lead to reduced caloric intake and subsequent weight loss in most patients

As of mid-2025, retatrutide has not received marketing authorisation in the United Kingdom, the European Union, or the United States

References- Umpierre D et al

AOD-9604, thanks to its mechanism (lipolysis directly from adipose tissue without effect on muscle cells), may help steer the weight reduction toward the fat component